DEA Delays Production Of Marijuana Drug As Potential Treatment For Multiple Sclerosis And Huntington's Disease
MMJ International Holdings, in collaboration with a specialty pharmaceutical solutions company, has been manufacturing gelatin capsule medicines based on compounds found in cannabis. The company will investigate these in clinical trials as potential treatments for multiple sclerosis (MS) and Huntington's disease (HD).
